Novel Immunotherapies for Solid Tumours
Event date and time: 3 October 2024, 9:30 am to 12:30 pm
Who should attend:
This content is ideal for research nurses, clinical nurse specialists, pharmacists, and clinical trials coordinators. It may also interest other healthcare professionals wanting to improve their understanding of immunotherapy.
This course emphasises the progress made in developing novel immunotherapies for solid tumours, such as CAR T cell therapy, TCR-engineered T cell therapy, tumour infiltrating lymphocytes, T cell engagers, and vaccine-based treatments.
Overview
An introduction to progress made in developing novel immunotherapies for solid tumours (excluding immune checkpoint inhibitors).
Over the course of one morning, Dr Elaine Vickers – a leading independent educator on the science of new cancer treatments – discusses novel approaches that may have a future as standard treatments for solid tumours including features of solid tumours that provoke the immune system and those that allow cancer cells to survive and thrive.
Elaine will describe cancers where novel immunotherapies are being most intensively explored, such as in the treatment of:
- cancers already known to be sensitive to immunotherapy, such as melanoma skin cancer
- cancers where new treatments are desperately needed, such as pancreatic cancer and glioblastoma
- cancers where a particularly promising target has been identified, such as Claudin 18.2 in stomach cancer and other GI cancers.
In the second session of the morning, Elaine focuses on cell-based immunotherapies such as TIL (tumour infiltrating lymphocyte) therapy, CAR T cell therapy, and TCR-engineered T cell therapy. She explains why we haven’t made more progress with these treatments and explores how this might change in the future.
In the final session, Elaine will examine some of the most innovative and exciting immunotherapies being developed, including T cell engagers and mRNA vaccines.